Translational Research Cancer Centers Consortium


The Translational Research Cancer Centers Consortium (TRCCC) mission is to gain a greater understanding of the interactions between the immune system and cancer in the setting of biologic therapy of cancer.


FEBRUARY 18-20, 2015

Johnathan Bramson, PhD.


TRCCC Event News

TRCCC receives support of AAI Young Investigator Awards through AAI Outreach Program.
The American Association of Immunologists (AAI) provides AAI Young Investigator Awards for either best oral presentation, or best poster presentation, by a student or a post-doctoral fellow through their outreach program. This year, AAI selected to support the awards for The TRCCC Annual Conference. The award includes a monetary award and a certificate. 

TRCCC Member News

AAI Newsletter Highlights Support of TRCCC through the AAI Outreach Program

The AAI Outreach Program supports member-organized immunotherapy meetings. In the September-October 2014 issue of the AAI Newsletter they focused on the TRCCC Annual Meeting. To view the article in its entirety, click here.
TRCCC Member Carl H. June Receives 2014 Career Award from The American Association of Immunologists
The American Association of Immunologists proudly announced the 2014 recipients of the AAI Awards for outstanding research and career achievements. TRCCC Member, Carl H. June, M.D., professor of patholo­gy and laboratory medicine at the Perelman School of Medicine and director of transla­tional research, Abramson Cancer Center at the University of Pennsylvania, received the 2014 AAI - Steinman Award for Human Immunology Research. This award recognizes an individual who has made significant contributions to the understanding of immune processes underlying human disease pathogenesis, prevention, or therapy. Congratulations Dr. June! To view the entier list of winners, please click here

Science Magazine Decalres Cancer Immunotherapy Breakthrough of the Year 2013
This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark. With much pressure these days to transform biological insights into lifesaving drugs, there's a lesson to be learned from immunotherapy's successes: They emerged from a careful decoding of basic biology that spanned many years. Read More

Roswell Park's Dr. Elizabeth Repasky Speaks to the New York Times about Recent Cancer Treatment Cleared By F.D.A
(December 3, 2013)
When federal regulators permitted the sale of an unproved device that uses intense heat to combat cancer, they did so for a compelling reason, to give hope to some women desperately ill with cervical cancer. However, Dr. Elizabeth Repasky, a hyperthermia expert at the Roswell Park Cancer Institute in Buffalo, said that she worried that the F.D.A.’s decision to approve the BSD-2000 without better data collection could set back the technology rather than advance it. Read More.

Roswell Park Cancer Institute, University of Pittsburgh Cancer Institute Awarded $11 Million SPORE Grant
(October 7, 2013)
With more than $11 million in funding from the National Cancer Institute, Roswell Park Cancer Institute in collaboration with University of Pittsburgh Cancer Institute, will embark on an aggressive, multi-pronged search for ways to prevent and cure it. Distributed over five years, the funds will come through a Specialized Program of Research Excellence (SPORE) grant. The research team, led by Kunle Odunsi, MD, PhD, Principal Investigator of the RPCI/UPCI Ovarian Cancer SPORE grant, will study novel immunotherapy approaches for the treatment of and risk assessment for ovarian cancer. The research itself will encompass four projects: three clinical trials evaluating newly developed immunotherapies and one epidemiological study looking for ways to reduce risk in women at high risk of developing ovarian cancer. For more information, click here.

Founding Director of the University of Pittsburgh Cancer Institute Passes Away
(June 5, 2013)
Ronald Herberman, who died Sunday at age 72, was probably more responsible than anyone for making UPCI what it is today -- a center whose 338 faculty members treat nearly 75,000 cancer patients a year, bringing in more than $155 million in research grants and conducting 250 separate clinical trials. Dr. Herberman came to Pittsburgh in 1985 from the National Cancer Institute in Bethesda, Md., where he had led ground-breaking research with natural killer cells that help a patient's immune system fight cancer. Read More.

To pay tribute to Dr. Ronald Herberman, his family requests that donations be made in his name to the Leukemia & Lymphoma Society. Click here to make a donation.

TRCCC Committee Member and Penn Researcher Wins Philadelphia Award
(June 01, 2013)
Carl June noted that the first genetic cause for leukemia was found in Philadelphia in 1960. Now, the University of Pennsylvania researcher hopes to make this the place where a cure is discovered for many leukemia patients. About 200 colleagues, friends, and patients touched by June's work gathered Friday evening at Penn's Perelman Center for Advanced Medicine to honor him as the 2012 recipient of the Philadelphia Award. Read More

Website Builder